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Abstract
Background: Evidence supporting the associations between folate metabolizing gene polymorphisms and
pancreatic cancer has been inconclusive. We examined their associations in a case-control study of Japanese
subjects.
Methods: Our case-control study involved 360 newly diagnosed pancreatic cancer cases and 400 frequency-matched,
non-cancer control subjects. We genotyped four folate metabolizing gene polymorphisms, including two
polymorphisms (rs1801133 and rs1801131) in the methylenetetrahydrofolate (MTHFR) gene, one polymorphism
(rs1801394) in the 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) gene and one
polymorphism (rs1805087) in the 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) gene. Genotyping
was performed using Fluidigm SNPtype assays. Unconditional logistic regression methods were used to estimate odds
ratios (ORs) and 95 % confidence intervals (CIs) for the associations between folate metabolizing gene variants and
pancreatic cancer risk.
Results: Overall we did not observe a significant association between these four genotypes and pancreatic
cancer risk. For rs1801133, compared with individuals with the CC genotype of MTHFR C677T, the OR for those
with the CT genotype and TT genotype was 0.87 (0.62-1.22) and 0.99 (0.65-1.51), respectively. For rs1801131,
individuals with the CC genotype had approximately 1.2-fold increased risk compared with those with the AA
genotype, but the association was not statistically significant. In analyses stratified by smoking and drinking
status, no significant associations were noted for C677T genotypes. No significant interactions were observed
with smoking and drinking with respect to pancreatic cancer risk.
Conclusions: Our data did not support the hypothesis that MTHFR polymorphisms or other polymorphisms in
the folate metabolizing pathway are associated with pancreatic cancer risk.
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Background
Pancreatic cancer is often diagnosed at an advanced stage
and has the poorest 5-year survival rate of any cancer.
There is no effective screening method to identify appar-
ently healthy individuals who are at risk for pancreatic
cancer. The etiology of pancreatic cancer remains largely
unknown, with only cigarette smoking and long standing
diabetes being established as risk factors [1]. The role of
diet in carcinogenesis has been recognized for a long time.
Evidence on the diet-pancreatic cancer associations from
epidemiologic studies remains elusive, in part because of
wide variation in dietary habits and the difficulty of accur-
ate diet measurement. In nutrient-based studies, there has
been much research interest in folate, a water soluble vita-
min B that is abundant in green leafy vegetables, citrus
fruit, legumes and cereals [2]. Folate plays a vital role in
maintaining health because it is closely involved in two
vital cellular processes, DNA methylation and DNA syn-
thesis [2]. Epidemiologic studies have linked folate defi-
ciency to a variety of conditions, including cardiovascular
diseases and cancer [3–5]. For pancreatic cancer, previous
studies have shown mixed findings on the association
between dietary folate intake and pancreatic cancer risk
[6–9], although a 2014 meta-analysis reported an inverse
association [10]. One possible reason for the inconsistent
findings is that folate status is determined by both dietary
folate intake and folate metabolism, making it difficult to
accurately quantify folate intake. Of numerous genes
involved in the folate metabolizing pathway, MTHFR has
been the most extensively studied [11, 12]. MTHFR irre-
versibly converts 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the predominant form of folate in
the circulation. Two variants in the MTHFR, namely
C677T (rs1801133) and A1298C (rs1801131), have been
the focus of most studies [11] because the variations are
associated with a small change in protein structure. Com-
pared with the CC genotype (wild-type), the TT genotype
(minor homozygotes) of C677T has approximately 35 %
lower enzyme activity and 10 % lower levels of methylhy-
drolate folate [11]. The 677 T variant has been associated
with numerous conditions, including elevated homocyst-
eine, spinal bifida, colon cancer, and Down syndrome [3]
As for MTHFR A1298C, the homozygous CC genotype
has approximately 60 % of normalMTHFR activity [12].
Evidence supporting the associations between folate me-
tabolizing gene polymorphisms and pancreatic cancer has
been inconclusive. To date, five case-control studies have
examined the association between the polymorphisms in
MTHFR, MTR, or MTRR genes and pancreatic cancer
risk, with conflicting results [13–17]. Of them, two case-
control studies conducted in Japan found no main effects
for polymorphisms in MTHFR (rs1801133, rs1801131),
MTR (rs1805087) or MTRR (rs1801394) genes [15, 17].
However, rs162049 in the MTRR gene, which encodes
enzymes responsible for DNA methylation, has been
shown to be associated with the susceptibility to pancre-
atic cancer in one previous Japanese case-control study
[17]. The significance of these polymorphisms in the folate
metabolizing pathway on pancreatic cancer remains to be
determined.
Given that substantial evidence from epidemiologic and
laboratory research supports an important role of folate in
carcinogenesis [18], we genotyped several genetic poly-
morphisms in the folate metabolizing pathway and exam-
ined their associations with pancreatic cancer risk in
Japanese subjects. We hypothesized that the variant
MTHFR C667T and A1298C genotypes resulting in de-
creased enzyme activity are associated with an increased
risk for pancreatic cancer. Additionally, we performed
analyses stratified by cigarette smoking and alcohol drink-
ing to address the possibility that these two lifestyle factors
may modify the associations between genetic polymor-
phisms and pancreatic cancer risk.
Methods
Study subjects
This case-control study was designed to address the role of
genetic variations in determining pancreatic cancer risk in
Japanese subjects. A detailed description of the study
method has been published elsewhere [19]. In brief, eligible
cases were defined as newly diagnosed pancreatic cancer
patients at five participating hospitals from April 1, 2010,
through May 15, 2012. Those who had received chemo-
therapy for pancreatic cancer prior to the study entry were
excluded. The diagnosis was based on imaging modalities
and pathology reports (if available) were further reviewed
for final diagnosis. Control subjects, who had no history of
cancer, were recruited from inpatients and outpatients at
each participating hospital, as well as from individuals who
underwent medical checkups at one of the participating
hospitals. The response rate was 85 % for cases and 98 %
for control subjects. The control subjects were frequency
matched to the case patients according to sex and age
(within 10-year categories). Finally, 360 case patients and
400 control subjects were included in the present analysis.
Approximately 90 % of tumors were histologically con-
firmed, with all tumors being adenocarcinomas.
For the main effect of genotypes, the sample size was
estimated using the following assumptions: multiplica-
tive genetic model, 10 % minor allele frequency, 0.1 %
disease prevalence, 1:1 case-control ratio, and OR = 2.0.
Then the number of cases required to achieve 90 %
power at a significance threshold of α = 0.05 was 190
cases [20]. This study was conducted in accordance with
the Helsinki Declaration. All the study subjects provided
written informed consent. The Ethics Board of Aichi
Medical University and the Institutional Review Board of
all the participating hospitals approved this study.
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Data collection
A self-administered questionnaire was used to solicit de-
tailed information on demographic characteristics, med-
ical history, and lifestyle factors such as smoking, drinking
and dietary habits. Dietary habits were surveyed using a
validated food frequency questionnaire (FFQ), in which
the study subjects were asked to describe the usual intake
frequency of 36 foods during the previous year prior to
the study entry [21]. After written informed consent was
obtained from the study subjects, a 7 mL venous blood
sample was collected. Genomic DNA was extracted using
the same protocol for cases and controls, and subse-
quently stored at -30 °C until analysis.
Genotyping assays
The genotyping of folate-metabolizing gene polymor-
phisms was performed using Fluidigm 192.24 Dynamic
Array with BioMark HD Systems and EP1 (Fluidigm
Corp., CA). SNPtype assay (Fluidigm Corp., CA), which
employs allele-specifically designed fluorescences (FAM
or VIC) primers and a common reverse primer, was used
in this study. Genotype calls were obtained using the
BioMark SNP Genotyping Analysis software. This soft-
ware defined the genotype of each sample based on the
relative intensities of fluorescences. The laboratory staff
members were blinded to case or control status. Four
quality control samples (negative control and positive
controls for major homozygote, heterozygote and minor
homozygote) were included in each assay, and the suc-
cessful genotyping rate was 100 %.
Statistical analysis
The differences in the characteristics of case patients and
control subjects were tested using t-test, Mann-Whitney
test, or chi-square test. The amount of daily ethanol intake
was calculated based on the frequency and amount of
alcohol beverages reported by the study subjects. The
amount of daily dietary folate intake was estimated based
on the responses to FFQ. A chi-square test was used to as-
sess the Hardy-Weinberg equilibrium (HWE) in control
subjects. Because the biological function of most SNPs has
not been clearly defined, a co-dominant genomic model
was assumed for SNP effects. Unconditional logistic re-
gression models were used to estimate odds ratios (ORs)
and 95 % confidence intervals (CIs) for the associations
between folate metabolism-associated genetic polymor-
phisms and pancreatic cancer risk. All analyses were
adjusted for age (continuous), sex (male or female), BMI
(<20, 20-22.4, 22.5-24.9, or ≧25.0), and cigarette smoking
(current, former, or never smokers). All tests were two-
tailed; a P value less than 0.05 was used to define statistical
significance. The interaction of genotype and smoking and
drinking with regard to pancreatic cancer risk was
assessed using a likelihood ratio test. All statistical
analyses were performed using SAS 9.12 (SAS Institute,
Inc., Cary, North Carolina, USA).
Results
The distribution of genotypes for all SNPs among con-
trol subjects did not deviate from HWE. The selected
characteristics of cases and controls are presented in
Table 1. Compared with control subjects, the cases were
more likely to have a history of diabetes and to be
current smokers. The proportion of current drinkers is
higher in control subjects than in case patients. The
daily ethanol intake was 24.1 g/d among case patients
and 17.5 g/d among control subjects. The median of
daily folate intake was 338.9 μg for case patients and
359.5 μg for control subjects. High intake of dietary fol-
ate was inversely associated with pancreatic cancer risk,
with OR of 0.52 (95 % CI: 0.33-0.82) among individuals
falling into the highest quartile when compare with
those falling into the lowest quartile.
Table 2 shows the ORs of pancreatic cancer in relation
to individual polymorphisms in the following genes:
MTHFR (rs1801133, rs1801131), MTRR (rs1801394),
and MTR (rs1805087). Overall no significant associa-
tions were noted between any single genotype and risk
of pancreatic cancer. For rs1801133, compared with
individuals with the CC genotype of MTHFR C677T, the
OR for those with the CT genotype and TT genotype
was 0.87 (0.62–1.22) and 0.99 (0.65–1.51), respectively.
For rs1801131, individuals with the CC genotype had
approximately 1.2-fold increased risk compared with
those with the AA genotype, but the association was not
statistically significant.
Table 3 shows the associations of pancreatic cancer
with folate metabolizing gene polymorphisms by smok-
ing and drinking status. There were no significant asso-
ciations in either never smokers or current smokers.
Similarly, there were no significant associations in either
never drinkers or current drinkers.
Table 4 shows the joint effects of smoking, drinking
and MTHFR genotypes on pancreatic cancer risk. No
significant interactions were observed for C667T geno-
types and cigarette smoking; the OR of pancreatic cancer
was 1.94 (1.05–3.57) for individuals who had the TT
genotype and were ever smokers. Similarly, no signifi-
cant interactions were noted for C677T genotypes and
alcohol drinking; the OR of pancreatic cancer was 1.05
(95 % CI: 0.62-1.78) for individuals who had the TT
genotype and were ever smokers.
Discussion
In this genetic case-control association study, we found
no statistically significant associations between polymor-
phisms in folate metabolizing gene pathways, including
MTHFR C677T and A1298C, and the risk of pancreatic
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cancer. Previous studies on the associations of MTHFR
(C677T) with pancreatic cancer risk have shown incon-
sistent results [13–16]. A hospital-based case-control
study, conducted at the MD Anderson Cancer Center in
the United States, found that individuals with the TT
variant genotype had a 2-fold increased risk for pancre-
atic cancer when compared with individuals with the CC
genotype [13]. A stronger association was reported in a
case-control study of Chinese population, in which the
OR was 5.12 for individuals with the TT genotype
Table 1 Characteristics of case patients and control subjects
Characteristics Case patients Control subjects P
(N = 360) (N = 400)
Age (mean ± SD) 67.8 ± 8.8 64.8 ± 9.5 <0.0001
Male, N (%) 215 (59.7) 226 (56.5) 0.58
Body mass index (kg/m2) (mean ± SD) 22.9 ± 3.3 22.8 ± 3.2 0.62
History of diabetes, N (%) <0.0001
No 269 (74.7) 362 (90.5)
Yes 87 (24.2) 35 (8.7)
Unknown 4 (1.1) 3 (0.8)
Smoking status, N (%) <0.0001
Non-smokers 145 (40.2) 202 (50.5)
Former smokers 119 (33.1) 140 (35.0)
Current Smokers 96 (26.7) 58 (14.5)
Alcohol drinking, N (%) 0.23
Non-drinkers 134 (37.2) 147 (36.8)
Former drinkers 24(6.7) 16 (4.0)
Current Drinkers 202(56.1) 237(59.2)
Ethanol intake (g/d), median (25th, 75th percentile) 24.1 (7.8, 48.9) 17.5 (5.7, 43.4) 0.02
Dietary folate intake (μg), median (25th, 75th percentile) 338.9 (280.9, 407.6) 359.2 (293.0, 438.8) 0.0007
SD, standard deviation
Table 2 Associations of pancreatic cancer with folate metabolizing gene polymorphisms
Case patients (n = 360) Control subjects (n = 400) Crude OR 95 % CI Multivariable-adjusted OR* 95 % CI P for trend**
MTHFR_C677T rs1801133
CC 127 124 1.00 1.00
CT 161 194 0.81 0.59-1.12 0.87 0.62-1.22
TT 72 82 0.86 0.57-1.28 0.99 0.65-1.51 0.86
MTHFR_A1298C rs1801131
AA 240 285 1.00 1.00
AC 107 102 1.25 0.90-1.72 1.28 0.91-1.80
CC 13 13 1.19 0.54-2.61 1.22 0.53-2.80 0.17
MTRR_A66G rs1801394
AA 167 206 1.00 1.00
AG 157 158 1.23 0.91-1.66 1.29 0.94-1.77
GG 36 36 1.23 0.74-2.04 1.12 0.66-1.91 0.27
MTR_A2756G rs1805087
AA 224 241 1.00 1.00
AG 117 142 0.89 0.65-1.20 0.87 0.63-1.21
GG 19 17 1.20 0.61-2.37 1.53 0.75-3.12 0.89
OR odds ratio, CI confidence interval
*OR was adjusted for age, sex, cigarette smoking, BMI, and history of diabetes
**P for trend is shown for multivariable-adjusted OR
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95 % CI P for interaction
MTHFR_C677T rs1801133 Never smokers Ever smokers
CC 48 63 1.00 79 61 1.00
CT 61 89 0.83 0.49-1.40 100 105 0.80 0.51-1.26
TT 36 50 0.91 0.50-1.66 36 32 1.02 0.55-1.87 0.94
MTHFR_A1298C rs1801131
AA 95 143 1.00 145 142 1.00
AC 45 53 1.39 0.84-2.29 62 49 1.24 0.78-1.96
CC 5 6 1.71 0.49-6.00 8 7 1.12 0.38-3.28 0.83
MTRR_A66G rs1801394
AA 61 101 1.00 106 105 1.00
AG 69 82 1.37 0.86-2.18 88 76 1.16 0.75-1.79
GG 15 19 1.21 0.56-2.62 21 17 1.09 0.52-2.26 0.46
MTR_A2756G rs1805087
AA 98 127 1.00 126 114 1.00
AG 41 69 0.73 0.44-1.19 76 73 1.08 0.70-1.66
GG 6 6 1.61 0.48-5.40 13 11 1.35 0.56-3.24 0.93
MTHFR_C677T rs1801133 Never drinkers Ever drinkers
CC 47 54 1.00 80 70 1.00
CT 58 66 1.05 0.60-1.82 103 128 0.74 0.48-1.16
TT 29 27 1.33 0.67-2.64 43 55 0.81 0.47-1.40 0.41
MTHFR_A1298C rs1801131
AA 88 101 1.00 152 184 1.00
AC 39 40 1.16 0.67-2.01 68 62 1.40 0.90-2.16
CC 7 6 1.43 0.44-4.61 6 7 1.06 0.32-3.55 0.78
MTRR_A66G rs1801394
AA 58 67 1.00 109 139 1.00
AG 56 66 1.03 0.61-1.73 101 92 1.45 0.96-2.19
GG 20 14 1.61 0.73-3.56 16 22 0.78 0.37-1.65 0.15
MTR_A2756G rs1805087
AA 87 86 1.00 137 155 1.00
AG 43 57 0.78 0.47-1.32 74 85 0.98 0.64-1.50
GG 4 4 1.49 0.35-6.38 15 13 1.59 0.69-3.65 0.57













compared with individuals with the CC genotype [14]. By
contrast, two previous case-control studies in Japan did
not find significant main effects for MTHFR C677T and
A1298C genotypes [15, 17]. Our null findings were in
agreement with results of these two previous studies. Our
null findings were also consistent with the conclusion of a
recent meta-analysis, which included all previous studies
and showed no significant main effects for both MTHFR
C677T and A1298C genotypes [22]. Furthermore, a recent
study has sought to examine 37 genes and 834 SNPs
related to one-carbon metabolism. There were no signifi-
cant associations for any of the SNPs after correction for
multiple comparisons [23]. However, in the case-control
study by Ohnami et al, rs162049 (intronic SNP) in the
MTRR gene showed significant associations after multiple
testing [17]. One strength of their study is that functional
tests were performed to collaborate the SNP-phenotype
association. Unfortunately, we did not genotype rs162049
in the MTRR gene, but further studies needs to replicate
their positive finding.
Given the lower enzymatic activity in individuals with
the variant TT genotype of MTHFR C677T, a key enzyme
in the folate metabolizing pathway, we hypothesized that
the TT genotype carriers have an increased risk of pancre-
atic cancer. Our results, however, showed that case
patients had a similar distribution of the TT genotypes
with that of control subjects, and neither CT nor TT ge-
notypes were significantly associated with the risk when
compared with CC genotypes. The reason for our null
findings on the associations between MTHFR genotypes
and pancreatic cancer risk is not clear, but the differences
observed in minor allele frequencies among ethnic groups
may in part account for the conflicting results. The geno-
type frequencies of MTHFR C677T differed between our
case-control study and the previous case-control study
that involved a US population [13]. Even though there
may be no main effects for the genotypes themselves, pre-
vious studies have shown that the MTHFR 677C→T
polymorphism is only associated with increased coronary
heart disease risk in a setting of low folate intake [4]. This
finding suggested that the effect modification by dietary
folate intake is important when interpreting the genotype-
disease associations. If nutritional folate status is poor, the
677 T variant might promote the misincorporation of ura-
cil into DNA, leading to genomic instability, a hallmark of
cancer [3]. This mechanism may, in part, account for the
increased cancer risk among individuals with the 677 T
variant of MTHFR. On the other hand, if folate intake is
adequate, the 677 T variant of MTHFR preferentially
routes one-carbon units to DNA synthesis at the expense
of methionine, which is involved in DNA methylation [3].
To address the possible effect modification by dietary fol-
ate intake, we evaluated their associations in low- versus
high- dietary intake group, and found no significant effect
modifications (data not shown). One possible reason is
that most subjects in our study had adequate dietary folate
intake because the estimated amount was comparable to
240 μg per day for Japanese adults recommended by the
government.
In addition to dietary folate intake, other lifestyle fac-
tors that may modify the associations between MTHFR
C677T and pancreatic cancer risk are smoking and
drinking. Because alcohol is known as a folate antagonist
and because smoking may impair folate status, several
studies have evaluated the joint effects of the MTHFR
polymorphisms with cigarette smoking or alcohol con-
sumption in relation to pancreatic cancer risk [13–15].
In one hospital-based case-control study conducted in
Japan, the risk of pancreatic cancer increased by 4.5-fold
among heavy drinkers with the MTHFR 677 CC geno-
type [15]. Similarly, another two case-control studies
found that individuals with the 677 T variant combined
Table 4 Joint effects of smoking, drinking and MTHFR C677T on pancreatic cancer risk
C677T Genotype Smoking Case patients Control subjects OR (95 % CI)
CC + CT Never 109 152 1.00
TT Never 36 50 1.04 (0.62-1.73)
CC + CT Ever 179 166 1.69 (1.13-2.54)
TT Ever 36 32 1.94 (1.05-3.57)
P for interaction = 0.79
Drinking Case patients Control subjects OR* (95 % CI)
CC + CT Never 105 120 1.00
TT Never 29 27 1.33 (0.72-2.45)
CC + CT Ever 183 198 1.10 (0.75-1.61)
TT Ever 43 55 1.05 (0.62-1.78)
P for interaction = 0.38
OR odds ratio, CI confidence interval
*OR was adjusted for age, sex, body mass index, cigarette smoking and history of diabetes
Nakao et al. BMC Gastroenterology  (2016) 16:83 Page 6 of 8
with heavy smoking or drinking had significantly in-
creased risk for pancreatic cancer [13, 14]. In contrast to
their findings, we failed to observe the synergistic effect
of the genotypes with either cigarette smoking or heavy
alcohol consumption. It is worth noting that the analysis
of gene-environment interaction was limited by a small
sample size in our study, as well as in those previous
studies. So the probability that the positive interaction
was due to chance cannot be ruled out.
Our study has several limitations. First, we had sufficient
number of cases required to detect significant associations
for the main effect of genotypes based on sample size esti-
mation; however, we did not have sufficient power to
detect significant associations in the analyses examining
the synergistic effect of genotypes and exposure of inter-
est. Assuming a dominant genetic model, a dichotomous
exposure prevalence of 10 %, a relative risk for a genotype
of 1.5, a relative risk for exposure of 1.5, and 1:1 case-
control ratio, we need thousands of cases and controls to
detect multiplicative interactions with relative risk of 2.0
[24]. Second, environmental exposure (folate) assessment
or environmental exposure (folate)-pancreatic cancer
association could have been affected by selection or recall
bias inherent in case-control studies; however, the
genotype-pancreatic cancer association was generally not
affected by bias due to differential environmental exposure
assessment between cases and control subjects. Third, the
lack of the data on plasma folate levels did not allow us to
address the relationship among MTHFR genotypes,
plasma levels and pancreatic cancer risk. It has been
shown that DNA methylation was affected by genotype
among only those with lower plasma folate levels [25].
Moreover, it is expected that multifactorial interactions
may exist among MTHFR genotypes, dietary folate, circu-
lating folate level, alcohol, and/or other relevant nutrients
including vitamin B2 and B12. Further studies need to
develop a novel analytical method addressing the complex
gene-environment interaction pathways involved in folate-
derived carcinogenesis.
Conclusions
In conclusion, our case-control study suggests that
there is no association between genetic polymorphisms
in folate-metabolizing genes and the risk of pancreatic
cancer in Japanese subjects. The results may not be
generalizable in view of limited sample size. Our study is
also limited to address effect modification by alcohol,
smoking or folate intake (gene-environment interaction)
because of inadequate statistical power.
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